​Collaborations and sister projects
Yellow4FLAVI collaborates with other scientific projects to advance research and innovation. Discover more about our partnerships and how we work together to enhance research outcomes in the fields of flaviviruses and pandemic preparedness.
_edited.png)
FLAVIVACCINE
Delivering a safe and effective protection against diseases resulting from mosquito-borne flavivirus infections
Flavivaccine will develop a novel prototype vaccine directed against several flaviviruses, define its immunogenicity and efficacy and prepare it for a future clinical evaluation. Instead of directly targeting the virus, this project focuses on the initial infection resulting from contact with mosquitoes.
​
Providing a single solution for multiple diseases, Flavivaccine has the potential to ease the economic and social burden of flaviviruses.
Our project creates a unique interdisciplinary environment, bringing together all the necessary scientific expertise and knowledge to address a critical problem on the rise.
​
LWNVIVAT
Limiting West Nile Virus Impact by Novel Vaccines And Therapeutics Approaches
LWNVIVAT project is a European Union-funded initiative aiming to develop an effective recombinant vaccine and therapeutic antibodies against the West Nile virus infection. Coordinated by the IrsiCaixa AIDS Research Institute, the project brings together a consortium of seven partners across Europe, including research centers and a pharmaceutical company. ​LWNVIVAT is utilizing computational tools to develop a recombinant vaccine and therapeutic antibodies targeting the West Nile virus, triggering an immune response that covers all variants. The project will also assess the efficacy of the developed antigens using in vitro, ex vivo and in vivo models.
​
SHIELD
Molecular Strategies against Viral Entry and Glycan Shielding
The SHIELD consortium targets two closely related steps in the viral replication cycle that are, as yet, difficult to study and to exploit for therapeutic interventions: 1) Virion glycosylation in the context of uptake, maturation and viral immunity. 2) Virion dynamics of entry into cells, where the plasticity of the involved proteins and their glycosylation status have key roles.
SHIELD studies viruses from the genera of flavivirus (DENV, WNV, YFV, Zika), mammarenaviruses (LASV) and henipaviruses (Hendra, Nipah). Integrating a broad spectrum of methodical expertise, SHIELD will develop molecular tools to prepare the EU for future pandemic events.
CONTAGIO
Empowering global response to outbreaks uniting experts worldwide to swiftly tackle infectious diseases, prioritizing low-resource settings
‘CONTAGIO (COhorts Network To be Activated Globally In Outbreaks) is a consortium of investigators from Europe, North America, Latin America, Asia, and Africa, coordinated by Dr. Thomas Jaenisch at the Universität Heidelberg. An EC HORIZON EUROPE 11 project funded by the European Commission.
CONTAGIO aims to create coordination mechanisms to rapidly react to infectious disease (re-)emergence in low- and middle-income countries. The Consortium builds on the experience acquired through the EC-funded projects ReCoDiD, ORCHESTRA, ZIKAlliance, and IDAMS. CONTAGIO acknowledges the critical connection between infectious diseases and climate change. The open science foreseen in CONTAGIO will create a coordination mechanism and framework for the role of sustainable cohorts in preparedness for (re-)emerging infectious diseases during interepidemic periods, which will be vital for the joint progress towards a better tackling of disease emergence aimed at the protection of citizens in LMICs, Europe and the rest of the world.
​